Literature DB >> 7969341

Rickettsialpox in a New York City hospital, 1980 to 1989.

E M Kass1, W K Szaniawski, H Levy, J Leach, K Srinivasan, C Rives.   

Abstract

BACKGROUND: Rickettsialpox is caused by Rickettsia akari, which is transmitted from rodents to humans by bloodsucking mites. The initial skin lesion forms an eschar and is followed by the development of fever, malaise, myalgia, and 5 to 40 maculopapules and papulovesicles. The disease, which responds to tetracycline, can be mistaken for chickenpox. The diagnosis has been based on an increase in serum antibody titers against R. akari over a period of three to eight weeks. We discuss a more rapid technique that uses direct immunofluorescence to identify R. akari in paraffin-embedded tissue, and we describe the histopathological findings of lesional skin.
METHODS: We studied 13 patients (age, 11 months to 58 years) who were seen at Lincoln Hospital in New York City from 1980 to 1989 and were suspected of having rickettsialpox. In nine patients serum samples were obtained during the acute and convalescent phases of the illness for indirect fluorescent-antibody testing. Punch-biopsy specimens of skin lesions were examined by microscopy and by direct fluorescent-antibody testing with an anti-R. rickettsii globulin conjugated with fluorescein isothiocyanate.
RESULTS: The diagnosis was confirmed in all 13 patients by indirect or direct fluorescent-antibody techniques. Direct fluorescent-antibody testing of eschars from seven patients was positive in five patients, but negative in two patients who had serologically confirmed rickettsialpox. In contrast, direct fluorescent-antibody testing of papulovesicles from nine patients was positive in only one patient. Histopathological analysis of the eschars revealed extensive necrosis and inflammation. In biopsy specimens of papulovesicles, dermal edema, subepidermal vesicles, and vascular changes were present.
CONCLUSIONS: The combination of direct fluorescent-antibody testing of an eschar from the presumed site of inoculation and histopathological examination of papulovesicles for distinctive features represents an improved method of diagnosing rickettsialpox.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969341     DOI: 10.1056/NEJM199412153312403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  8 in total

Review 1.  Detection of infection or infectious agents by use of cytologic and histologic stains.

Authors:  G L Woods; D H Walker
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

Review 2.  The Rickettsioses: A Practical Update.

Authors:  Lucas S Blanton
Journal:  Infect Dis Clin North Am       Date:  2019-03       Impact factor: 5.982

Review 3.  Rickettsioses as paradigms of new or emerging infectious diseases.

Authors:  D Raoult; V Roux
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

4.  The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax.

Authors:  Wun-Ju Shieh; Jeannette Guarner; Christopher Paddock; Patricia Greer; Kathleen Tatti; Marc Fischer; Marci Layton; Michael Philips; Eddy Bresnitz; Conrad P Quinn; Tanja Popovic; Bradley A Perkins; Sherif R Zaki
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

5.  Genomic study of Rickettsia akari by pulsed-field gel electrophoresis.

Authors:  M Eremeeva; N Balayeva; V Ignatovich; D Raoult
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

Review 6.  Rickettsial infections of the central nervous system.

Authors:  Zuzana Sekeyová; Monika Danchenko; Peter Filipčík; Pierre Edouard Fournier
Journal:  PLoS Negl Trop Dis       Date:  2019-08-29

7.  Rickettsialpox in North Carolina: a case report.

Authors:  Allan Krusell; James A Comer; Daniel J Sexton
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

8.  Rickettsialpox in Turkey.

Authors:  Mustafa K Ozturk; Tamer Gunes; Mehmet Kose; Christopher Coker; Suzana Radulovic
Journal:  Emerg Infect Dis       Date:  2003-11       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.